AstraZeneca sees group sales fall, operating profit rises
AstraZeneca has reported that group sales for 2011 were down while operating profit saw a rise, reflecting double digit sales growth for Crestor, Seroquel XR and Symbicort.
AstraZeneca has reported that group sales for 2011 were down while operating profit saw a rise, reflecting double digit sales growth for Crestor, Seroquel XR and Symbicort.
The drugs giant said sales were down 2%, at constant exchange rates, to $33,591m (2010: $33,269m) while reported operating profit was up 10% at $12,795m (2010: $11,494m).
Revenue in the US was down 2%, down 11% in Western Europe, and up 10% in emerging markets. Reported earnings per share were up 29% at $7.33 (2010: $5.60). Core operating profit was down 4%.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
In a statement the firm said: "The world pharmaceutical market grew by 4.5% in 2011 and the fundamentals of the industry remain strong. While the fundamentals remain strong, the challenges facing the industry have been unprecedented in recent years. Patents on some of the world's most successful innovative medicines are starting to expire and we face increasing competition from generic alternatives.
"We are confident that long-term growth in demand for innovative biopharmaceuticals will remain strong. We continue to plan on the basis that revenue will be in the range of $28-34bn a year over the 2010-14 period, as revenue growth from key franchises that retain exclusivity and continued growth in emerging markets are pressured by the loss of market exclusivity on a number of products."
The share price fell 0.21% to 2,834.00p.
NR
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.
-
8 of the best houses for sale with tennis courts
The best houses for sale with tennis courts – from a period property in Dumfries and Galloway with two islands on the River Dee, to a house in Cumbria with a 1977 En Tout Cas tennis court
-
Review: Eden Roc Cap Cana – fun, sun and golf in the Caribbean
Travel Eden Roc Cap Cana in the Dominican Republic offers everything from relaxing by the pool to a world-class golf course